27 results on '"Ahn, Sylvie A."'
Search Results
2. Prognostic Value of Pulmonary Transit Time by Cardiac Magnetic Resonance on Mortality and Heart Failure Hospitalization in Patients With Advanced Heart Failure and Reduced Ejection Fraction.
- Author
-
Houard L, Amzulescu MS, Colin G, Langet H, Militaru S, Rousseau MF, Ahn SA, Vanoverschelde JJ, Pouleur AC, and Gerber BL
- Subjects
- Belgium epidemiology, Female, Follow-Up Studies, Heart Failure mortality, Heart Failure physiopathology, Humans, Male, Middle Aged, Predictive Value of Tests, Prognosis, Prospective Studies, Survival Rate trends, Heart Failure diagnosis, Hospitalization trends, Magnetic Resonance Imaging, Cine methods, Risk Assessment methods, Stroke Volume physiology, Ventricular Function, Left physiology, Ventricular Function, Right physiology
- Abstract
Background: Pulmonary transit time (PTT) from first-pass perfusion imaging is a novel parameter to evaluate hemodynamic congestion by cardiac magnetic resonance (cMR). We sought to evaluate the additional prognostic value of PTT in heart failure with reduced ejection fraction over other well-validated predictors of risk including the Meta-Analysis Global Group in Chronic Heart Failure risk score and ischemic cause., Methods: We prospectively followed 410 patients with chronic heart failure with reduced ejection fraction (61±13 years, left ventricular (LV) ejection fraction 24±7%) who underwent a clinical cMR to assess the prognostic value of PTT for a primary endpoint of overall mortality and secondary composite endpoint of cardiovascular death and heart failure hospitalization. Normal reference values of PTT were evaluated in a population of 40 asymptomatic volunteers free of cardiovascular disease. Results PTT was significantly increased in patients with heart failure with reduced ejection fraction as compared to controls (9±6 beats and 7±2 beats, respectively, P <0.001), and correlated not only with New York Heart Association class, cMR-LV and cMR-right ventricular (RV) volumes, cMR-RV and cMR-LV ejection fraction, and feature tracking global longitudinal strain, but also with cardiac output. Over 6-year median follow-up, 182 patients died and 200 reached the secondary endpoint. By multivariate Cox analysis, PTT was an independent and significant predictor of both endpoints after adjustment for Meta-Analysis Global Group in Chronic Heart Failure risk score and ischemic cause. Importantly in multivariable analysis, PTT in beats had significantly higher additional prognostic value to predict not only overall mortality (χ
2 to improve, 12.3; hazard ratio, 1.35 [95% CI, 1.16-1.58]; P <0.001) but also the secondary composite endpoints (χ2 to improve=20.1; hazard ratio, 1.23 [95% CI, 1.21-1.60]; P <0.001) than cMR-LV ejection fraction, cMR-RV ejection fraction, LV-feature tracking global longitudinal strain, or RV-feature tracking global longitudinal strain. Importantly, PTT was independent and complementary to both pulmonary artery pressure and reduced RV ejection fraction<42% to predict overall mortality and secondary combined endpoints., Conclusions: Despite limitations in temporal resolution, PTT derived from first-pass perfusion imaging provides higher and independent prognostic information in heart failure with reduced ejection fraction than clinical and other cMR parameters, including LV and RV ejection fraction or feature tracking global longitudinal strain. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03969394.- Published
- 2021
- Full Text
- View/download PDF
3. Additional Prognostic Value of 2D Right Ventricular Speckle-Tracking Strain for Prediction of Survival in Heart Failure and Reduced Ejection Fraction: A Comparative Study With Cardiac Magnetic Resonance.
- Author
-
Houard L, Benaets MB, de Meester de Ravenstein C, Rousseau MF, Ahn SA, Amzulescu MS, Roy C, Slimani A, Vancraeynest D, Pasquet A, Vanoverschelde JJ, Pouleur AC, and Gerber BL
- Subjects
- Aged, Cause of Death, Female, Heart Failure mortality, Heart Failure physiopathology, Humans, Male, Middle Aged, Predictive Value of Tests, Prognosis, Registries, Retrospective Studies, Risk Assessment, Risk Factors, Time Factors, Echocardiography, Heart Failure diagnostic imaging, Magnetic Resonance Imaging, Cine, Stroke Volume, Ventricular Function, Left
- Abstract
Objectives: This study sought to compare the prognostic value of 2-dimensional (2D) right ventricular (RV) speckle tracking (STE) against cardiac magnetic resonance (CMR) RV ejection fraction (EF) and feature tracking (FT) and conventional echocardiographic parameters on overall and cardiovascular (CV) survival in patients with heart failure with reduced EF (HFrEF)., Background: Prior works showed that RV systolic function predicts prognosis in HFrEF. 2D RVSTE had recently been proposed as new echocardiographic method to evaluate RV dysfunction., Methods: A total of 266 patients with HFrEF (mean LVEF 23 ± 7%, 60 ± 14 years of age; 29% women) underwent RV function assessment using CMR and 2D echocardiography and were followed for a primary endpoint of overall death and secondary endpoint of CV death., Results: Average CMR-RVEF was 42 ± 15%, average STE RV global longitudinal strain (STE-RVGLS) was -18.0 ± 4.9%, and average CMR-FT-RVGLS was -11.8 ± 4.3%. After a median follow-up of 4.7 years, 102 patients died, 84 of a CV cause. RVEF, FT-RVGLS, tricuspid annulus plane systolic excursion (TAPSE), fractional area change (FAC), and STE-RVGLS were significant univariate predictors of overall and cardiac death. In multivariate Cox regression, age, ischemic etiology, diabetes, New York Heart Association functional class III to IV, and beta-blocker treatment were independent clinical predictors of overall mortality. CMR-RVEF (chi-square to enter = 3.9; p < 0.05), FT-RVGLS (chi-square to enter 3.7; p = 0.05), FAC (chi-square to enter 6.2; p = 0.02), and TAPSE (chi-square to enter = 4.1; p = 0.04) provided additional prognostic value over these baseline parameters, but the additional predictive value of STE-RVGLS (chi-square to enter = 10.8; p < 0.001) was significantly (p < 0.05) higher than the other tests. Additional hazard ratio to predict overall mortality was 2.5 (95% confidence interval [CI]: 1.6 to 3.9) for STE-RVGLS <-19%, 2.15 (95% CI: 1.34 to 3.43) for TAPSE >15 mm, 1.6 (95% CI: 1.02 to 2.49) for FAC >39%, 1.93 (95% CI: 1.25 to 2.99) for RVEF >41%, and 1.87 (95% CI: 1.10 to 3.19) for CMR-FT-RVGLS <-15%., Conclusions: 2D RVGLS provides strong additional prognostic value to predict overall and CV mortality in HFrEF, with higher predictive value than CMR-RVEF, CMR-FT-RVGLS, TAPSE, or FAC. This supports use of STE-RVGLS to identify higher-risk HFrEF patients., (Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
4. Incremental value of intact fibroblast growth factor 23 to natriuretic peptides for long-term risk estimation of heart failure patients.
- Author
-
Gruson D, Carbone V, Feracin B, Ahn SA, and Rousseau MF
- Subjects
- Aged, Belgium, Biomarkers blood, Cardiomyopathy, Dilated physiopathology, Female, Fibroblast Growth Factor-23, Follow-Up Studies, Heart Failure diagnosis, Heart Failure etiology, Heart Failure mortality, Humans, Immunoassay, Male, Middle Aged, Myocardial Ischemia physiopathology, Practice Guidelines as Topic, Prognosis, Risk Assessment, Severity of Illness Index, Stroke Volume, Fibroblast Growth Factors blood, Heart physiopathology, Heart Failure blood, Natriuretic Peptide, Brain blood, Peptide Fragments blood
- Abstract
Fibroblast growth factor 23 (FGF-23), a key hormone for the regulation of the phosphorus homeostasis, has also several direct effects on cardiac function. In heart failure (HF), the increase of FGF-23 participates to cardiac hypertrophy and remodeling. Measurement of the intact, biologically active hormone is now available. We determined intact FGF-23 in HF patients with reduced ejection fraction and assess its prognosis value for cardiovascular death over a long-term follow-up. We observed that intact FGF-23 is an independent predictor of cardiovascular death in HF patients and provides added value to the standard of care, natriuretic peptide, for risk estimation., (Copyright © 2018 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
5. Head to head comparison of intact and C-terminal fibroblast growth factor 23 in heart failure patients with reduced ejection fraction.
- Author
-
Gruson D, Ferracin B, Ahn SA, and Rousseau MF
- Subjects
- Aged, Biomarkers blood, Disease Progression, Enzyme-Linked Immunosorbent Assay, Female, Fibroblast Growth Factor-23, Follow-Up Studies, Heart Failure diagnosis, Heart Failure physiopathology, Humans, Male, Retrospective Studies, Time Factors, Fibroblast Growth Factors blood, Heart Failure blood, Stroke Volume physiology
- Published
- 2017
- Full Text
- View/download PDF
6. Elevation of plasma oncostatin M in heart failure.
- Author
-
Gruson D, Ferracin B, Ahn SA, and Rousseau MF
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers blood, Female, Fibroblast Growth Factor-23, Humans, Male, Middle Aged, Stroke Volume physiology, Ventricular Dysfunction, Left physiopathology, Heart Failure blood, Oncostatin M blood, Ventricular Dysfunction, Left blood
- Abstract
Aim: Oncostatin M (OSM) is an inflammatory cytokine of the gp130 family. OSM could participate in adverse cardiovascular remodeling through regulation of FGF23., Materials & Methods: OSM levels were determined in 80 heart failure patients with reduced left ventricular ejection fraction (HFrEF)., Results: OSM levels are significantly increased in HFrEF patients compared with healthy subjects. We have also demonstrated that, in HFrEF patients, plasma OSM levels are correlated to parathyroid hormone PTH(1-84) and 1,25(OH)
2 D, two other biomarkers related to bone and mineral metabolism and associated to adverse cardiovascular outcomes., Conclusion: OSM concentrations are elevated in HFrEF patients and could interplay with parathyroid hormone and vitamin D impacting cardiovascular function. Nevertheless, the prognostic value of OSM testing appears limited.- Published
- 2017
- Full Text
- View/download PDF
7. Testing for Soluble ST2 in Heart Failure Patients: Reliability of a Point of Care Method.
- Author
-
Gruson D, Ferracin B, Ahn SA, and Rousseau MF
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers blood, Blood Proteins, Enzyme-Linked Immunosorbent Assay, Female, Galectin 3 blood, Galectins, Heart Failure blood, Humans, Male, Middle Aged, Natriuretic Peptide, Brain blood, Parathyroid Hormone blood, Peptide Fragments blood, Predictive Value of Tests, Prognosis, Reproducibility of Results, Severity of Illness Index, Young Adult, Heart Failure diagnosis, Interleukin-1 Receptor-Like 1 Protein blood, Point-of-Care Systems, Point-of-Care Testing
- Abstract
Background: Our objective was to determine soluble ST2 (sST2) concentrations in heart failure (HF) patients with a point-of-care (POCT) assay., Methods: sST2 levels were measured in 71 HF patients with both POCT and ELISA methods. The concentrations of sST2 were correlated to HF severity and to some established biomarkers of cardiovascular risk., Results: sST2 levels measured with the ASPECT-PLUS POCT method were significantly correlated with the comparison ELISA assay (r = 0.94, p < 0.01) and were related to HF severity. Levels of sST2 measured with the POCT assay were significantly correlated to NT-proBNP (r = 0.57, p < 0.001), BNP (r = 0.75, p < 0.001), Galectin-3 (r = 0.40, p < 0.01) and PTH (1-84) (r = 0.39, p < 0.01)., Conclusions: POCT and ELISA methods for sST2 testing were significantly correlated, and our results confirmed also the clinical reliability of the sST2 POCT assay. Furthermore, the POCT method allows a faster delivery of results to physicians.
- Published
- 2017
- Full Text
- View/download PDF
8. Sflt-1 in heart failure: relation with disease severity and biomarkers.
- Author
-
Gruson D, Hermans MP, Ferracin B, Ahn SA, and Rousseau MF
- Subjects
- Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 2 metabolism, Female, Healthy Volunteers, Humans, Male, Middle Aged, Natriuretic Peptide, Brain, Peptide Fragments, Severity of Illness Index, Biomarkers blood, Heart Failure blood, Heart Failure diagnosis, Heart Failure physiopathology, Placenta Growth Factor blood, Vascular Endothelial Growth Factor Receptor-1 blood
- Abstract
Soluble fms-like tyrosine kinase-1 (sFlt-1) is an endogenous inhibitor of endothelial growth factors, such as placental growth factor (PlGF), which modulates cardiovascular (CV) remodeling. We determine sFlt-1 levels in patients with heart failure (HF) and its relationship to adverse cardiovascular (CV) events and biomarkers of cardiovascular risk. Levels of sFlt-1 and PlGF levels were also determined in healthy volunteers and patients with type 2 diabetes mellitus (T2DM). SFlt-1 and PlGF were clearly increased in HF patients in comparison to T2DM patients or healthy subjects (p < 0.01). Concentration of sFlt-1 was related to HF severity (p < 0.001) and was correlated to NT-proBNP (ρ = 0.37, p < 0.01), soluble ST2 (ρ = 0.52, p < 0.01), Galectin-3 (ρ = 0.38, p < 0.01), aldosterone (ρ = 0.25, p = 0.01) and PTH(1-84) (ρ = 0.38, p < 0.01). Furthermore, sFlt-1 levels were associated to long-term CV risk. These results suggest a potential role of sFlt-1 in HF and its potential role as biomarker of CV risk.
- Published
- 2016
- Full Text
- View/download PDF
9. 1,25-Dihydroxyvitamin D to PTH(1-84) Ratios Strongly Predict Cardiovascular Death in Heart Failure.
- Author
-
Gruson D, Ferracin B, Ahn SA, Zierold C, Blocki F, Hawkins DM, Bonelli F, and Rousseau MF
- Subjects
- Adult, Aged, Aged, 80 and over, Chronic Disease mortality, Female, Heart Failure mortality, Humans, Male, Middle Aged, Prognosis, Vitamin D blood, Young Adult, Heart Failure blood, Heart Failure diagnosis, Parathyroid Hormone blood, Vitamin D analogs & derivatives
- Abstract
Objectives: Vitamin D deficiency and hyperparathyroidism are common in patients with heart failure (HF). There is a growing body of evidence supporting the role of vitamin D and parathyroid hormone (PTH) in cardiac remodeling and worsening of HF. Lack of reliable automated testing of 1,25-dihydroxyvitamin D (1,25(OH)2D), the biologically active metabolite of vitamin D, has limited its contribution to the prognostic assessment of HF. Here, the association of 1,25(OH)2D and PTH(1-84) levels was evaluated for prediction of cardiovascular death in chronic HF patients., Methods: We conducted a single center prospective cohort including 170 chronic HF patients (females n = 36; males n = 134; NYHA II-IV; mean age: 67 years; etiology: ischemic n = 119, dilated cardiomyopathy n = 51; mean LVEF: 23%). The primary outcome was cardiovascular death., Results: Serum levels of 1,25(OH)2D decreased markedly with increased HF severity. Medians were 33.3 pg/mL for NYHA-II patients, 23.4 pg/mL for NYHA-III, and 14.0 pg/mL for NYHA-IV patients (p<0.001). Most patients had levels of 25(OH)D below 30ng/mL, and stratification by NYHA functional class did not show significant differences (p = 0.249). The 1,25(OH)2D to PTH(1-84) ratio and the (1,25(OH)2D)2 to PTH(1-84) ratio were found to be the most significantly related to HF severity. After a median follow-up of 4.1 years, 106 out of 170 patients reached the primary endpoint. Cox proportional hazard modeling revealed 1,25(OH)2D and the 1,25(OH)2D to PTH(1-84) ratios to be strongly predictive of outcomes., Conclusions: 1,25(OH)2D and its ratios to PTH(1-84) strongly and independently predict cardiovascular mortality in chronic HF.
- Published
- 2015
- Full Text
- View/download PDF
10. Comparison of fibroblast growth factor 23, soluble ST2 and Galectin-3 for prognostication of cardiovascular death in heart failure patients.
- Author
-
Gruson D, Ferracin B, Ahn SA, and Rousseau MF
- Subjects
- Aged, Biomarkers blood, Female, Fibroblast Growth Factor-23, Glomerular Filtration Rate, Heart Failure physiopathology, Humans, Interleukin-1 Receptor-Like 1 Protein, Male, Middle Aged, Prognosis, Survival Analysis, Fibroblast Growth Factors blood, Galectin 3 blood, Heart Failure blood, Receptors, Cell Surface blood
- Published
- 2015
- Full Text
- View/download PDF
11. Multiple biomarker strategy based on parathyroid hormone and natriuretic peptides testing for improved prognosis of chronic heart failure.
- Author
-
Gruson D, Ahn SA, and Rousseau MF
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers blood, Chronic Disease, Female, Humans, Male, Middle Aged, Prognosis, Risk, Young Adult, Heart Failure diagnosis, Natriuretic Peptides blood, Parathyroid Hormone blood
- Abstract
Biomarkers offer new perspectives for a more personalized management of patients with heart failure (HF). Hyperparathyroidism is common in HF patients and parathyroid hormone (PTH) testing might provide added value for the prognostication of HF patients. Our objectives were therefore to determine the efficiency of multiple biomarker strategy based on PTH and natriuretic peptides measurement for the risk stratification of patients with HF. Circulating concentrations of bioactive PTH 1-84 and natriuretic peptides, B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP), were measured with automated immunoassays in 45 healthy individuals and 137 HF patients with reduced left ventricular ejection fraction. Circulating levels of PTH 1-84 and natriuretic peptides were significantly increased in HF patients in comparison to HF patients. Over a long-term follow-up, baseline PTH 1-84 levels were related to the risk of cardiovascular death. Furthermore, in multiple biomarker approach, PTH measurement was additive to BNP and NT-proBNP testing for the cardiovascular risk assessment of HF patients. In conclusion, the combination of PTH 1-84 and natriuretic peptides testing improves the prognostication of HF patients and might allowed more personalized approach for risk stratification and treatment selection in HF patients., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
12. Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction.
- Author
-
Gruson D, Lepoutre T, Ahn SA, and Rousseau MF
- Subjects
- Aged, Aged, 80 and over, Biomarkers blood, Female, Follow-Up Studies, Heart Failure diagnosis, Humans, Interleukin-1 Receptor-Like 1 Protein, Male, Middle Aged, Predictive Value of Tests, Survival Rate trends, Time Factors, Death, Heart Failure blood, Heart Failure mortality, Natriuretic Peptides blood, Receptors, Cell Surface blood, Stroke Volume physiology
- Published
- 2014
- Full Text
- View/download PDF
13. Measurement Nt-proBNP circulating concentrations in heart failure patients with a new point-of-care assay.
- Author
-
Lepoutre T, Rousseau MF, Ahn SA, and Gruson D
- Subjects
- Humans, Biomarkers blood, Heart Failure blood, Natriuretic Peptide, Brain blood, Peptide Fragments blood, Point-of-Care Systems
- Abstract
Background: BNP (Brain Natriuretic Peptide) and Nt-proBNP (N-terminal-pro-Brain Natriuretic Peptide) are valuable markers for the diagnosis and prognosis of heart failure (HF). The AQT90 FLEX is a newly released random access analyzer for point-of-care (POCT) measurement. The aim of our study was to determine Nt-pro-BNP concentrations in HF patients with the POCT assay., Methods: Nt-proBNP levels were measured in seventy seven HF patients and in thirty seven healthy volunteers. The results were compared with a central laboratory assay., Results: Nt-proBNP levels measured with the AQT90 FLEX were significantly correlated with the comparison Nt-proBNP assay and were related to HF severity., Conclusions: Nt-proBNP testing with the AQT 90 FLEX analyzer is comparable to the central lab assay and may offer the advantages of POCT testing for the diagnosis and prognosis of heart failure.
- Published
- 2013
- Full Text
- View/download PDF
14. Measurement of NT-proBNP with LOCI technology in heart failure patients.
- Author
-
Gruson D, Ahn SA, Lepoutre T, and Rousseau MF
- Subjects
- Adult, Aged, Biomarkers metabolism, Cardiology methods, Clinical Laboratory Techniques methods, Female, Humans, Immunoassay methods, Male, Middle Aged, Oxygen chemistry, Radioimmunoassay methods, Time Factors, Heart Failure drug therapy, Natriuretic Peptide, Brain analysis, Peptide Fragments analysis
- Abstract
Objectives: The aim of our study was to determine NT-proBNP concentrations in heart failure (HF) patients with a luminescent oxygen channeling immunoassay (LOCI)., Design and Methods: Seventy HF patients were enrolled. NT-proBNP levels were measured with LOCI method and compared to a reference NT-proBNP assay., Results: LOCI NT-proBNP levels were significantly correlated with the reference NT-proBNP assay and were related to HF severity., Conclusions: LOCI assay demonstrates performances close to the comparative assay for NT-proBNP testing and allows a significant reduction of the time of analysis., (Copyright © 2011. Published by Elsevier Inc.)
- Published
- 2012
- Full Text
- View/download PDF
15. Increased plasma myostatin in heart failure.
- Author
-
Gruson D, Ahn SA, Ketelslegers JM, and Rousseau MF
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers, Case-Control Studies, Female, Heart Failure diagnosis, Heart Failure pathology, Humans, Male, Middle Aged, Muscle, Skeletal metabolism, Myostatin biosynthesis, Myostatin metabolism, Statistics as Topic, Transforming Growth Factor beta metabolism, Heart Failure blood, Myostatin blood, Transforming Growth Factor beta blood
- Abstract
Aims: Myostatin (Mstn), a member of the transforming growth factors (TGF)-β family that regulate skeletal muscle growth, has been identified as a regulator of cardiomyocyte growth. The aim of our study was to measure Mstn plasma concentrations in patients with congestive heart failure (CHF) and to evaluate their relationship with other neurohormones released in CHF., Methods and Results: concentrations of Mstn were measured using a competitive immunoassay, in 76 CHF patients who were receiving optimal treatment and 60 healthy controls. Circulating levels of other neurohormones N-terminal pro-atrial natriuretic peptide (NT-proANP), B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and Big ET-1 were also measured. Plasma Mstn was higher in CHF patients than in controls (63.0 vs. 43.0 ng/mL; P < 0.001). In CHF, Mstn levels correlated positively with NT-proANP (r=0.25; P=0.03), BNP (r=0.33; P<0.01), NT-proBNP (r=0.32; P<0.01), and Big ET-1 (r=0.26; P=0.02). No significant correlations were observed with age and creatinine., Conclusion: Our results demonstrate that plasma concentrations of Mstn are significantly increased in CHF patients and that Mstn correlates with biomarkers related to HF severity. Our study confirms the activation of Mstn in patients with heart failure.
- Published
- 2011
- Full Text
- View/download PDF
16. Biomarkers of inflammation and cardiac remodeling: the quest of relevant companions for the risk stratification of heart failure patients is still ongoing.
- Author
-
Gruson D, Ahn SA, and Rousseau MF
- Subjects
- Biomarkers metabolism, Cardiomegaly diagnosis, Cardiomegaly epidemiology, Cardiomegaly etiology, Heart Failure epidemiology, Heart Failure metabolism, Humans, Inflammation metabolism, Models, Biological, Predictive Value of Tests, Professional Practice trends, Risk Assessment methods, Risk Factors, Biomarkers analysis, Diagnostic Techniques, Cardiovascular trends, Heart Failure diagnosis, Heart Failure etiology, Inflammation diagnosis, Ventricular Remodeling physiology
- Abstract
Heart failure (HF) is a frequent chronic disease in elderly people and represents a major health and economic burden. The accurate diagnosis of HF and the identification of high risk patients is mandatory to select the appropriate therapy and care. HF is associated to cardiac remodeling and inflammation and to the release of neurohormones. If natriuretic peptides remain the biomarkers of choice for the diagnosis and the prognosis of HF, several biomarkers related to cardiac remodeling and inflammation are available for testing and may add valuable information for the risk estimation of HF patients and for the selection of the most appropriated therapy. Furthermore, the quest for new efficient biomarkers of cardiac remodeling and inflammation is still ongoing and new candidates have been identified for a potential use in daily clinical practices. However, before their potential translation to routine parameters several challenges ranging form the analytical validation to the cost-effectiveness estimation should be considered.
- Published
- 2011
- Full Text
- View/download PDF
17. Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study.
- Author
-
Van Beneden R, Gurné O, Selvais PL, Ahn SA, Robert AR, Ketelslegers JM, Pouleur HG, and Rousseau MF
- Subjects
- Female, Humans, Immunoradiometric Assay, Male, Middle Aged, Prognosis, Atrial Natriuretic Factor blood, Endothelin-1 blood, Heart Failure blood, Heart Failure mortality, Natriuretic Peptide, Brain blood
- Abstract
Background: Plasma concentrations of atrial and brain natriuretic peptides (ANP, BNP), of their N-terminal pro-peptides, of endothelin-1 (ET-1), and big endothelin-1 (big ET-1) have diagnostic and prognostic significance in congestive heart failure (CHF). However, their respective values as a predictor of survival remain controversial and have never been directly compared in severe CHF., Methods and Results: We analyzed, in 47 patients with severe CHF (New York Heart Association [NYHA] class III to IV; age 66 +/- 8 years, ejection fraction 20 +/- 6%), the prognostic performance of a panel of neurohormones and assays (N-terminal pro-ANP 1-25, 68-98 by radioimmunoassay [RIA], and 1-98 by enzyme-linked immunosorbent assay [ELISA], BNP by RIA and immunoradiometric assay [IRMA], N-terminal pro-BNP by Elisa, ET-1 by RIA, and big ET-1 by RIA and Elisa. Data were compared with 40 patients with mild to moderate CHF [NYHA I-II] and 30 healthy subjects. After a follow-up of 81 +/- 15 months, there were 34 deaths and 1 heart transplant. All neurohormones were significantly higher at baseline in patients with severe than in mild to moderate CHF or healthy subjects (all P < .001). Although all neurohormones but BNP IRMA were significant predictors of survival in univariate analysis, only big ET-1 RIA and ET-1 were independent predictors of survival (improvement chi(2): 7.5 and 4.6, P < .01 and P < .05). Using medians as cutpoints of big ET-1 RIA and ET-1, 2 severe CHF populations were defined with a different outcome (5-year survival: 55 versus 18%, P < .01)., Conclusions: Big ET-1 and ET-1 are strong independent predictors of survival in patients with severe CHF and better for this purpose than natriuretic peptides or their pro-peptides. These markers allow easily to identify a population with a very high risk mortality eligible for more aggressive therapies.
- Published
- 2004
- Full Text
- View/download PDF
18. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study.
- Author
-
Jong P, Yusuf S, Rousseau MF, Ahn SA, and Bangdiwala SI
- Subjects
- Cause of Death, Female, Follow-Up Studies, Heart Failure etiology, Heart Failure mortality, Humans, Male, Middle Aged, Ventricular Dysfunction, Left complications, Ventricular Dysfunction, Left mortality, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Enalapril therapeutic use, Heart Failure drug therapy, Life Expectancy, Ventricular Dysfunction, Left drug therapy
- Abstract
Background: In the studies of left ventricular dysfunction (SOLVD), enalapril reduced mortality in patients with symptomatic but not asymptomatic left ventricular systolic dysfunction during the trial. We did a 12-year follow-up of SOLVD to establish if the mortality reduction with enalapril among patients with heart failure was sustained, and whether a subsequent reduction in mortality would emerge among those with asymptomatic ventricular dysfunction., Methods: Of the 6797 patients previously enrolled in the SOLVD prevention and treatment trials, we ascertained the subsequent vital status of 5165 individuals who were alive when the trials had been completed. Follow-up was done through direct contacts in Belgium and linkages with national death registries and federal beneficiary or historic tax summary files in the USA and Canada., Findings: Follow-up was 99.8% (6784/6797) complete. In the prevention trial, 50.9% (1074/2111) of the enalapril group had died compared with 56.4% (1195/2117) of the placebo group (generalised Wilcoxon p=0.001). In the treatment trial, 79.8% (1025/1285) of the enalapril group had died compared with 80.8% (1038/1284) of the placebo group (generalised Wilcoxon p=0.01). The reductions in cardiac deaths were significant and similar in both trials. When data for the prevention and treatment trials were combined, the hazard ratio for death was 0.90 for the enalapril group compared with the placebo group (95% CI 0.84-0.95, generalised Wilcoxon p=0.0003). Enalapril extended median survival by 9.4 months in the combined trials (95% CI 2.8-16.5, p=0.004)., Interpretation: Treatment with enalapril for 3-4 years led to a sustained improvement in survival beyond the original trial period in patients with left ventricular systolic dysfunction, with an important increase in life expectancy.
- Published
- 2003
- Full Text
- View/download PDF
19. The Increase of Soluble Urokinase Plasminogen Activator Receptor in Heart Failure is Related to Disease Severity and Cardiac Mortality
- Author
-
Gonda, Judit, Aaddi, Nisrine, Ahn, Sylvie, Rousseau, Michel, and Gruson, Damien
- Published
- 2024
- Full Text
- View/download PDF
20. Heart-type fatty acid binding protein is related to severity and established cardiac biomarkers of heart failure
- Author
-
Gruson Damien, Adamantidou Christina, Ahn Sylvie A., and Rousseau Michel F.
- Subjects
biomarker ,heart failure with reduced ejection fraction (hfref) ,heart failure ,nt-probnp ,outcome ,risk ,Medical technology ,R855-855.5 - Abstract
To determine concentrations of heart-type fatty acid-binding protein (HFABP) in patients with heart failure with reduced ejection fraction (HFrEF) and its potential value for prognostic assessment.
- Published
- 2021
- Full Text
- View/download PDF
21. Performances of a novel chemiluninescence ABEI-based NT-proBNP immunoassay.
- Author
-
Adamantidou, Christina, Ahn, Sylvie, Rousseau, Michel, and Gruson, Damien
- Subjects
NATRIURETIC peptides ,IMMUNOASSAY ,HEART failure ,EARLY diagnosis - Abstract
Natriuretic peptides are widely used in clinical practice as cardiac markers for early diagnosis, prognosis and for the monitoring of treatment efficiency of heart Failure (HF). According to the clinical relevance of natriuretic peptides testing, it is important to assess the performances of novel platform for testing. Our study showed the overall good performances of a new NT-proBNP ABEI-based automated immunoassay. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. Additional Prognostic Value of 2D Right Ventricular Speckle-Tracking Strain for Prediction of Survival in Heart Failure and Reduced Ejection Fraction: A Comparative Study With Cardiac Magnetic Resonance
- Author
-
Houard, Laura, Benaets, Marie Bénédicte, de Meester de Ravenstein, Christophe, Rousseau, Michel F., Ahn, Sylvie A., Amzulescu, Mihaela Silvia, Roy, Clotilde, Slimani, Alisson, Vancraeynest, David, Pasquet, Agnes, Vanoverschelde, Jean Louis J., Pouleur, Anne Catherine, Gerber, Bernhard L., UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de pathologie cardiovasculaire, and Cardiology
- Subjects
Survival ,Radiology Nuclear Medicine and imaging ,Speckle-tracking echocardiography ,heart failure ,Heart failure ,CMR ,Cardiology and Cardiovascular Medicine ,survival ,speckle-tracking echocardiography - Abstract
OBJECTIVES: This study sought to compare the prognostic value of 2-dimensional (2D) right ventricular (RV) speckle tracking (STE) against cardiac magnetic resonance (CMR) RV ejection fraction (EF) and feature tracking (FT) and conventional echocardiographic parameters on overall and cardiovascular (CV) survival in patients with heart failure with reduced EF (HFrEF). BACKGROUND: Prior works showed that RV systolic function predicts prognosis in HFrEF. 2D RVSTE had recently been proposed as new echocardiographic method to evaluate RV dysfunction. METHODS: A total of 266 patients with HFrEF (mean LVEF 23 ± 7%, 60 ± 14 years of age; 29% women) underwent RV function assessment using CMR and 2D echocardiography and were followed for a primary endpoint of overall death and secondary endpoint of CV death. RESULTS: Average CMR-RVEF was 42 ± 15%, average STE RV global longitudinal strain (STE-RVGLS) was -18.0 ± 4.9%, and average CMR-FT-RVGLS was -11.8 ± 4.3%. After a median follow-up of 4.7 years, 102 patients died, 84 of a CV cause. RVEF, FT-RVGLS, tricuspid annulus plane systolic excursion (TAPSE), fractional area change (FAC), and STE-RVGLS were significant univariate predictors of overall and cardiac death. In multivariate Cox regression, age, ischemic etiology, diabetes, New York Heart Association functional class III to IV, and beta-blocker treatment were independent clinical predictors of overall mortality. CMR-RVEF (chi-square to enter = 3.9; p < 0.05), FT-RVGLS (chi-square to enter 3.7; p = 0.05), FAC (chi-square to enter 6.2; p = 0.02), and TAPSE (chi-square to enter = 4.1; p = 0.04) provided additional prognostic value over these baseline parameters, but the additional predictive value of STE-RVGLS (chi-square to enter = 10.8; p < 0.001) was significantly (p < 0.05) higher than the other tests. Additional hazard ratio to predict overall mortality was 2.5 (95% confidence interval [CI]: 1.6 to 3.9) for STE-RVGLS 15 mm, 1.6 (95% CI: 1.02 to 2.49) for FAC >39%, 1.93 (95% CI: 1.25 to 2.99) for RVEF >41%, and 1.87 (95% CI: 1.10 to 3.19) for CMR-FT-RVGLS
- Published
- 2019
23. Value of proBNP1–108 testing for the risk stratification of patients with systolic heart failure.
- Author
-
Gruson, Damien, Lepoutre, Thibault, Ahn, Sylvie A., and Rousseau, Michel F.
- Subjects
- *
HEART failure patients , *BRAIN natriuretic factor , *RISK assessment , *FOLLOW-up studies (Medicine) , *CARDIOVASCULAR diseases , *NESIRITIDE - Abstract
Highlights: [•] ProBNP1–108, BNP and Nt-proBNP levels were measured in patients with systolic heart failure (HF). [•] Their predictive value for long-term survival was assessed through an 8 years follow-up. [•] ProBNP1–108 levels were markedly increased in patients with systolic HF. [•] The highest proBNP levels were related to patients with the highest risk of CV death. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
24. Soluble ST2, the vitamin D/PTH axis and the heart: New interactions in the air?
- Author
-
Gruson, Damien, Ferracin, Benjamin, Ahn, Sylvie A., and Rousseau, Michel F.
- Subjects
- *
VITAMIN D receptors , *HEART failure treatment , *INTERLEUKIN-33 , *PARATHYROID hormone-related protein , *BIOMARKERS , *GENE expression - Published
- 2016
- Full Text
- View/download PDF
25. SOLUBLE RECEPTOR FMS LIKE TYROSINE KINASE 1 TESTING IN HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION.
- Author
-
Gruson, Damien, Ferracin, Benjamin, Ahn, Sylvie, and Rousseau, Michel
- Subjects
- *
PROTEIN-tyrosine kinase inhibitors , *HEART failure , *ENDOTHELIAL growth factors , *BIOMARKERS , *VENTRICULAR remodeling , *NATRIURETIC peptides - Published
- 2015
- Full Text
- View/download PDF
26. C-terminal FGF23 is a strong predictor of survival in systolic heart failure
- Author
-
Gruson, Damien, Lepoutre, Thibault, Ketelslegers, Jean-Marie, Cumps, Jean, Ahn, Sylvie A., and Rousseau, Michel F.
- Subjects
- *
FIBROBLAST growth factors , *HEART failure patients , *PHOSPHATE metabolism , *CALCIUM metabolism regulation , *GLOMERULAR filtration rate , *PARATHYROID hormone , *FOLLOW-up studies (Medicine) - Abstract
Abstract: Fibroblast growth factor 23 (FGF23) is a bone-derived hormone involved in the regulation of phosphate and calcium metabolism. We have evaluated the levels of C-terminal FGF23 (Ct-FGF23) in 73 patients presenting heart failure with reduced ejection fraction (HF-REF) and assess their potential predictive value for long-term survival through a 6years follow-up. Ct-FGF23 levels were markedly increased in HF-REF. In univariate proportional hazard model, survival was related to glomerular filtration rate (eGFR), intact parathyroid hormone (PTH), B-type natriuretic peptides (BNP) and Ct-FGF23. In a multivariate analysis including age, EF, PTH, BNP, Ct-FGF23, calcium, phosphorus and eGFR levels, Ct-FGF23 is the strongest predictor of long term CV death. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
27. Cardiac and hemodynamic effects of intravenous dofetilide in patients with heart failure.
- Author
-
Rousseau, Michel F., Massart, Pierre-E, van Eyll, Christian, Etienne, Jean, Ahn, Sylvie, Ghadanfar, Mathieu, Friedrich, Tilman, Pouleur, Hubert, Rousseau, M F, Massart, P E, van Eyll, C, Etienne, J, Ahn, S, Ghadanfar, M, Friedrich, T, and Pouleur, H
- Subjects
- *
MYOCARDIAL depressants , *LEFT heart ventricle , *HEMODYNAMICS , *HEART failure - Abstract
This study assesses the effects of dofetilide, a new selective Ikr blocker with class III properties, on left ventricular function and hemodynamics of heart failure and compares these effects with those of placebo and amiodarone. Because available antiarrhythmic drugs may depress myocardial performance, an invasive hemodynamic study was performed to assess the safety of this agent. Hemodynamic and angiographic data were obtained at baseline and after 30 minutes of double-blind infusion of dofetilide (8 microg/kg; n = 12), placebo (n = 12), or amiodarone (5 mg/kg; n = 6) in heart failure patients (New York Heart Association class II or III, ejection fraction <35%). Intravenous dofetilide preserved the inotropic indexes and the end-systolic volume index despite a slight but significant decrease in heart rate, whereas intravenous amiodarone increased end-diastolic and end-systolic volume indexes. Amiodarone induced a negative inotropic effect illustrated by a rightward shift of the pressure-volume loop and a reduction in pressure-derived indexes of contractility. Intravenous dofetilide acutely prolonged QT interval more than intravenous amiodarone; however, dofetilide did not slow the overall relaxation rate and reduced QT dispersion. In an acute setting, compared with intravenous amiodarone, intravenous dofetilide preserves cardiac function offering a hemodynamic advantage to treat arrhythmias in patients with impaired left ventricular function. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.